Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANDA Modifications: US FDA Wants More Formal Facility-Initiated Withdrawals

Executive Summary

Facilities that cannot coax an ANDA sponsor to amend their application to exclude a center will have to convince a "less comfortable" FDA with a larger record.

You may also be interested in...



How US FDA's Assumptions Impacted Generic Program Fees

FDA decided against trying to predict upcoming approvals as part of FY 2019 GDUFA program fee calculations, but other adjustments likely increased fee significantly.

ANDA Submissions To US FDA Expected To Decline; Generic User Fees For FY 2019 Will Rise

FDA's predictions have been pretty consistent; actual submissions haven't been.

No More 'Hidden' Facilities, US FDA Tells Generic Sponsors

Agency officials don't care if DMF holder doesn't give access to its entire facility list; FDA says industry is responsible for listing all facilities that could be used as part of ANDA.

Related Content

Topics

UsernamePublicRestriction

Register

PS125121

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel